The Week in Review #41
We Are Still Witnessing …
The bizarre market performance that started in early 2019: In the past couple of months the great enthusiasm and response of the market to the undeniably strong economic indicators and the lowest unemployment figures turned, for mysterious reasons, to a perturbed-looking volatile market beast. The biotech stocks have given back most of their deserved gains during repeated The Wcrashes that no professional could explain.
Unfair downgrades have badly hurt firms whose quarterly financial reports have beaten analysts exaggerated expectations and firms that have been for a long time . . .